|
Monks, Terrence J; Jones, Douglas C; Bai, Fengju et al. (2004) The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 26:132-6
|
|
Jones, Douglas C; Lau, Serrine S; Monks, Terrence J (2004) Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J Pharmacol Exp Ther 311:298-306
|
|
Monks, T J; Bai, F; Miller, R T et al. (2001) Serotonergic neurotoxicity of methylenedioxyamphetamine and methylenedioxymetamphetamine. Adv Exp Med Biol 500:397-406
|
|
Monks, T J; Ghersi-Egea, J F; Philbert, M et al. (1999) Symposium overview: the role of glutathione in neuroprotection and neurotoxicity. Toxicol Sci 51:161-77
|
|
Monks, T J; Lau, S S (1998) The pharmacology and toxicology of polyphenolic-glutathione conjugates. Annu Rev Pharmacol Toxicol 38:229-55
|
|
Miller, R T; Lau, S S; Monks, T J (1997) 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 323:173-80
|
